Use Bupropion XL (Extended-Release)
For your 33-year-old patient with depression who failed sertraline and escitalopram, prescribe Bupropion XL (extended-release), not XR. "XL" and "XR" are often used interchangeably in clinical parlance, but the FDA-approved formulation for depression is specifically Bupropion Hydrochloride Extended-Release Tablets (XL), dosed once daily 1.
Key Prescribing Details
Bupropion XL is the correct formulation because:
- FDA-approved specifically for major depressive disorder at once-daily dosing 1
- The XL formulation allows for once-daily administration, improving adherence
- Starting dose: 150 mg once daily in the morning
- Target dose: 300 mg once daily (can increase after 4 days if tolerated)
- Maximum dose: 450 mg once daily (though 300 mg is typically sufficient) 1
Why This Matters for Your Patient
After failing two SSRIs (sertraline and escitalopram), switching to a different mechanism of action is appropriate. Bupropion is a norepinephrine-dopamine reuptake inhibitor, offering a distinct pharmacologic approach 2. The 2008 American College of Physicians guideline supports selecting second-generation antidepressants based on adverse effect profiles and patient preferences, noting that bupropion has significantly lower rates of sexual dysfunction compared to SSRIs 3.
Research directly supports this switch strategy: A study of fluoxetine-resistant patients switched to bupropion SR showed 60% achieved full or partial response, with 35% achieving full remission 4. Additionally, bupropion XL demonstrated non-inferiority to escitalopram in head-to-head trials while maintaining superior sexual tolerability 5, 6.
Critical Safety Monitoring
Absolute Contraindications (Do Not Prescribe If Present):
- Seizure disorder or history of seizures - bupropion lowers seizure threshold 1
- Current or prior eating disorder (anorexia nervosa or bulimia) 1
- Abrupt alcohol or benzodiazepine discontinuation 1
- MAOI use within 14 days 1
Monitor Closely For:
- Suicidal ideation - especially in first 1-2 weeks and with any dose changes 1
- Blood pressure elevation - can occur, particularly if combined with nicotine replacement 1
- Neuropsychiatric symptoms - agitation, anxiety, panic attacks, insomnia, irritability 1
- Manic symptoms - increased energy, racing thoughts, decreased sleep need 1
Dosing Algorithm
Week 1: Start 150 mg once daily in the morning
Week 2-4: Continue 150 mg if tolerated; can increase to 300 mg after 4 days if needed
Week 5-8: Target dose 300 mg once daily
Assessment at 6-8 weeks: If inadequate response, consider increasing to 450 mg once daily (maximum dose) or switching/augmenting strategy 3
Common Pitfalls to Avoid:
- Do not split or crush tablets - this is an extended-release formulation 1
- Do not dose late in the day - can cause insomnia 2
- Do not combine with other bupropion products (Wellbutrin SR, Zyban, Aplenzin, Forfivo XL) - risk of overdose and seizures 1
- Do not abruptly discontinue at 450 mg dose - taper over at least 1 week 7
Advantages for This Patient
Given the SSRI failures, bupropion XL offers several benefits:
- Different mechanism of action - targets norepinephrine and dopamine rather than serotonin 8
- Minimal sexual dysfunction - major advantage over SSRIs, with rates comparable to placebo (13-16% vs. 8-11%) 6
- No weight gain - unlike many SSRIs 8
- May improve energy and concentration - particularly helpful if patient has these symptoms 2
- Once-daily dosing - better adherence than multiple daily doses
When to Reassess
At 1-2 weeks: Monitor for suicidality, agitation, worsening depression 1
At 6-8 weeks: Assess response using standardized measures (PHQ-9 or HAM-D). If inadequate response (less than 50% symptom reduction), consider:
- Increasing to 450 mg daily if on 300 mg
- Switching to another antidepressant class
- Augmentation strategies (though evidence for specific augmentation with bupropion is limited) 3, 9
The 2023 ACP guideline emphasizes that modification of treatment is warranted if inadequate response by 6-8 weeks 9.